Home › Trials › NCT06463665

New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Phase 2 Interventional Genelux Corporation · NCT06463665

This study is testing a new treatment that combines a special virus and chemotherapy to see if it can help people with advanced lung cancer who haven't responded to previous treatments.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment142 (estimated)
Ages18 Years and up
SexAll
SponsorGenelux Corporation Industry-sponsored
Drugs / interventionsimatinib, chemotherapy, prednisone, immunotherapy
Locations16 sites (Bullhead City, Arizona and 15 other locations)
Trial IDNCT06463665 on ClinicalTrials.gov

What this trial studies

This Phase 2, open-label, randomized study evaluates the efficacy and safety of Olvimulogene Nanivacirepvec, an oncolytic virus, combined with platinum-doublet chemotherapy and a physician's choice of immune checkpoint inhibitor, compared to docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). Participants must have experienced disease progression while on prior treatments and have measurable tumors. The study aims to determine if this combination can enhance immune activation and resensitize tumors to chemotherapy. It includes patients with both squamous and non-squamous NSCLC without known targetable genetic alterations.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with advanced or metastatic NSCLC who have shown disease progression after initial treatment.

Not a fit: Patients with known targetable genetic alterations in EGFR, ALK, or ROS1 may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced non-small-cell lung cancer who have limited treatment options.

How similar studies have performed: Other studies using oncolytic viruses and immunotherapy have shown promise, suggesting potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female 18 years or older.
* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
* Have histologically or cytologically confirmed advanced or metastatic NSCLC.
* Histologically confirmed Stage III or IV squamous or nonsquamous \[American Joint Committee on Cancer (AJCC) 8th edition\].
* Received at least 2 cycles and maximum of 6 cycles of front-line platinum-based chemotherapy with ICI-based therapy, regardless of PD-L1 expression.
* Reached first disease progression by radiological assessment while receiving front-line or maintenance ICI.
* At least one measurable target tumor lesion anywhere except the brain per RECIST 1.1 by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.
* Have adequate renal, hepatic, bone marrow function as well as adequate coagulation tests \[International Normalized Ratio (INR)\] and adequate immune function by lymphocyte count.
* Women of child-bearing potential must have a negative serum pregnancy test prior to initiating study dosing.
* Be willing and able to comply with scheduled visits, the treatment plan, imaging and laboratory tests.

Exclusion Criteria:

* Active and untreated urinary tract infection, pneumonia, or other systemic infections.
* Current symptomatic central nervous system (CNS) metastasis.
* Any uncontrolled systemic disease, condition or comorbidity that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
* Persistent toxicities \[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3\] caused by previous anticancer therapy; alopecia and vitiligo are excluded toxicities.
* Required the use of additional immunosuppression other than corticosteroids for the management of an adverse event or have experienced recurrence of an adverse event if re-challenged, or currently require maintenance doses of \>10 mg prednisone or equivalent per day.
* Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, tecovirimat, or other agents with known anti-vaccinia activities).
* Underwent major surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to the planned first dose of treatment in either Arm.
* Have received prior virus-based gene therapy or therapy with cytolytic virus of any type.
* Vaccination against smallpox or monkeypox within 1 year of study therapy.
* Any non-oncology vaccine therapy used for prevention of infectious diseases, such as seasonal (influenza) vaccinations, corona virus disease (COVID) vaccination or other vaccines, within 2 weeks of the planned first dose of study drug.
* Clinically significant skin disease as assessed by the Investigator (e.g., severe eczema, psoriasis, or any unresolved skin injury or ulcer).
* Known hypersensitivity to carboplatin, cisplatin, paclitaxel or nab-paclitaxel, docetaxel, or any of the constituents of Olvi-Vec (i.e., gentamicin).
* Had severe hypersensitivity (CTCAE Grade ≥ 3) to ICI and/or any of its excipients previously.
* Dementia or altered mental status that would prohibit informed consent, and/or psychiatric illness/social situations that might interfere or limit compliance with study requirements.

Where this trial is running

Bullhead City, Arizona and 15 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.